MERZ-THERAPEUTICS
wMerz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced today that they have entered into a strategic license and collaboration agreement for the delivery of botulinum neurotoxin A (Xeomin®) ) to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder and interstitial cystitis and other urology indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005052/en/
Stefan Brinkmann, CEO Merz Therapeutics: “This strategic, long-term partnership with the Israeli Start-up Vensica allows us to expand into the attractive market of overactive bladder. It perfectly reflects the potential and capabilities of our neurotoxin platform for the development of sizeable non-movement disorder indications, pursuing our promise to create better outcomes for more patients. We strongly believe in the innovative and less invasive treatment of bladder diseases using Vensica’s ultrasound-assisted delivery catheter and are therefore looking forward to bringing this new treatment option to the patients together with our partner Vensica.”
Vensica CEO, Avner Geva commented, “We are very excited about our strategic partnership with Merz. By licensing Merz’s Botulinum Toxin A, Xeomin® , we’ve achieved an important milestone in our journey to changing the lives of urological patients. We hope that together with Merz, we will be able to provide, needle-less and minimal invasive procedures to over 85 million patients around the world, enabling them to benefit from a minimal discomfort, anesthesia-free, outpatient experience. The partnership with Merz, which includes not only exclusive licensing of Xeomin® , but also development support, enables us to accelerate our clinical trials and regulatory process. We are thrilled Merz realized the potential and need and chose to invest in innovative medical technologies that can benefit patients worldwide.”
“The collaboration with Vensica is a great example for our Merz Corporate Venture Capital Initiative,” states Jörg Bergler, COO Merz Group. “Here, we are investing globally in companies who are pursuing innovative, breakthrough science. As an experienced partner, we are not only granting Vensica access to our toxin but also offer know-how and experience for the development and preparation of the regulatory approval process in an advisory capacity."
The long-term partnership includes Merz’s intention to participate and invest in Vensica. Under the terms of the agreement, Merz already received, in addition to royalties, equity shares from Vensica with the option for further investment in the upcoming years and will be represented with a seat in the Board of Directors. Vensica will be responsible for the pre-clinical and clinical development of the needleless device and will prepare and file the marketing approval application. Upon the marketing approval, Merz will be responsible for the manufacturing and supply of Xeomin® (incobotulinumtoxinA) and Vensica will manage commercial activities worldwide, except of Japan.
Vensica’s proprietary ultrasound-assisted drug delivery system is an innovative minimally invasive solution to urology. The system enables needleless delivery of drugs to the bladder wall in a simple and quick procedure. The platform drives treatment from the surgical center to the private clinics, as it removes the need for a highly trained urologist, staff, and anesthesia. The unique delivery profile enables uniform delivery of the neurotoxin to greater area of the bladder wall, which may increase its efficacy, such as earlier onset and longer effect. The device is at clinical development stage by Vensica Therapeutics an Israeli based company.
Xeomin® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm or hypersalivation. Merz uses state-of-the-art technology in its dedicated facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing. The highly purified neurotoxin, the only active ingredient in Xeomin® , is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin® to reduce the production of neutralizing antibodies capable of lowering efficacy.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs.
About Vensica Therapeutics Ltd.
Vensica is a urology therapeutics company based out of Israel. The company is developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system. The company was founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc) and is led and backed by medical and therapeutic’s leaders, including chairman M.D., Ph.D, Nissim Darvish, Lew Pell, Laborie and The Trendlines Group.
About Merz
Merz Group is a global, diversified company based in Frankfurt, Germany, with the three businesses Merz Aesthetics, Merz Therapeutics and Merz Consumer Care. The company is family-owned for over 112 years and is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. In fiscal year 2019/20 (June 30), Merz generated revenue of EUR 981.5 million. The company employs 3,212 people in 28 countries worldwide. To learn more, please visit www.merz.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom